clinical-trials-2017-scientifictracks-abstracts

32 / 46

Page 73
Notes:
conferenceseries.com
Volume 7, Issue 5 (Suppl) J Clin Trials, an open access journal
ISSN:2167-0870 Clinical Trials 2017
September 11-13, 2017
September 11-13, 2017 San Antonio, USA
4th International Conference on
Cl inical Tr ial s
Bangladesh: Can be a potential new hub for global CROs for global clinical trials
Wasif Ali Khan
Icddr, b, Bangladesh
Lower costs to conduct clinical trials and availability of treatment-naïve patients have attracted many pharmaceutical
companies to conduct clinical trials in developing countries in Africa, China, India, and parts of Eurasia. However, despite
having a large patient base and diverse disease profiles, until recently Bangladesh could not appropriately participate in global
clinical trials due to the lack of clinical research infrastructure. In a recently conducted study in lupus nephritis (LN) study
conducted over 80 sites from 23 countries – Bangladesh was included as second tier when recruitment was alarmingly slowwith
the first tier. LN is a rare disease requiring the use of a global approach to recruitment. The total time required in Bangladesh
to obtain central as well as the site IRB approvals was 4 months. Although the initial country target was to enroll a maximum
of 25 patients from Bangladesh, quality in clinical care and ensuring the ICH-GCP guidelines were closely and constantly
maintained allowed for an increase in countrywide enrollment. This resulted in ultimate highest patient enrollment from
Bangladesh (n=46) out of total n=265 patients enrolled globally. In this study 80% of clinical studies fail to meet enrollment
deadlines, and 50% of sites enroll 1 or no patients.
Bangladesh a country of over 160 million with many treatment naïve patients; increased number of lifestyle diseases are
emerging with the change of the economy of the country from low to middle income country. Young physician Investigator has
themedical training in English and trained in the same standard as UK Investigators.The combination of population availability,
high quality Investigators and the common use of English points to Bangladesh as a potential new hub for international clinical
trials and global CROs to explore in this newly emerged clinical research country. That results in faster recruitment, saving
unnecessary investigations and reducing overall study cost. Most importantly new drugs those are in the pipeline are evaluated
much faster through Clinical trials for regulatory approval and thus the neediest patients are privileged with newer medicines
that could benefit both morbidity and mortality.
Biography
Wasif Khan, medical graduate from Bangladesh obtained Graduate Training Program in Clinical Investigation (GTPCI) from Johns Hopkins Univ. (JHU). He
completed fellowship in Clinical Pharmacology from Division of Pharmacology, JHU as Merck International Fellow. He has over 26 years of experience in Clinical
Trials. He is leading the clinical trial unit of icddr, b; pioneers opportunities for multi-national Pharmaceuticals and global CROs to explore Bangladesh as a new
hub for clinical trials. Constantly interacts / delivers presentations related to this venture in different local institutes and maintains close liaison with the relevant
authorities of Govt. of Bangladesh. He has published more than 90 papers in peer reviewed journals.
Wasif Ali Khan, J Clin Trials 2017, 7:5 (Suppl)
DOI: 10.4172/2167-0870-C1-019